Stryker Corp. 10-Q Summary: Q1 2026
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Stryker Corporation, a global leader in medical technologies, operates in two reportable segments: MedSurg and Neurotechnology and Orthopaedics. During Q1 2026, the company announced a reorganization creating a new "Ortho Tech" business, combining orthopaedic instruments with Mako and enabling technologies. Historical data has been recast to reflect this structure.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Sales | $6,020 million | $5,866 million |
| Gross Profit | $3,810 million | $3,744 million |
| Operating Income | $936 million | $837 million |
| Net Earnings | $745 million | $654 million |
| Diluted EPS | $1.93 | $1.69 |
| Operating Cash Flow | $581 million | $250 million |
| Total Debt | $14,723 million | $15,859 million |
| Cash and Equivalents | $2,878 million | $4,011 million |
Margins: Gross margin was 63.3% (down from 63.8%); Operating margin was 15.5% (up from 14.3%).
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 2.6% year-over-year (1.0% in constant currency). MedSurg and Neurotechnology grew 5.0%, while Orthopaedics remained flat at 0.1%.
- Profitability: Net earnings rose 13.9% to $745 million. However, adjusted operating income margin contracted 180 basis points to 21.1% due to higher costs.
- Cash Flow: Operating cash flow more than doubled to $581 million, driven by working capital changes. Investing cash outflows decreased significantly to $185 million compared to $4,136 million in 2025, as the prior year included the $4.7 billion Inari acquisition.
- Debt Reduction: Total debt decreased by $1,136 million, primarily due to the repayment of $1,000 million in senior unsecured notes maturing in March 2026.
Outlook, Risks, and Unusual Items
Cybersecurity Incident: On March 11, 2026, Stryker identified a cybersecurity incident that disrupted business operations and caused idle production time. Management determined this had a material impact on Q1 financial results, specifically increasing manufacturing and supply chain costs. Operations have been restored, but the investigation is ongoing.
Acquisitions: In May 2026, the company acquired Amplitude Vascular Systems, Inc. (AVS) for approximately $435 million in cash plus up to $400 million in milestones to expand its vascular portfolio.
Macro Environment: The company faces risks from new U.S. tariffs and trade policy changes, though a Supreme Court ruling in 2026 struck down certain previous tariffs, creating uncertainty regarding potential refunds.
Guidance: The filing does not provide specific forward-looking numerical guidance for the full year 2026, referencing instead the risks associated with the cybersecurity incident and macroeconomic factors.
Investor Verification Checklist
- Cybersecurity Impact: Verify the full extent of financial impact from the March 2026 incident and any potential future operational disruptions or remediation costs.
- Margin Pressure: Monitor whether the 180 basis point contraction in adjusted operating margin is a one-time event or indicative of sustained higher manufacturing costs.
- Debt Maturity Wall: Review the debt schedule for upcoming maturities, noting the recent repayment of $1 billion and the remaining $14.7 billion in total debt.
- Organizational Restructuring: Assess the integration progress of the new "Ortho Tech" business unit and its impact on future segment reporting.
- Acquisition Integration: Track the integration of the AVS acquisition and the performance of the Inari Medical portfolio within the Vascular business.